Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines

Allergan45 enrolled

Overview

This study evaluates the patient satisfaction and onset of effect following treatment with botulinum toxin Type A in the treatment of glabellar rhytids (frown lines)

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Skin Aging

Interventions

botulinum toxin Type ABIOLOGICAL

20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)

Eligibility

Sex: FEMALEMin age: 35 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female subjects of any race, 35-55 years of age * Moderate to severe glabellar wrinkles (lines between the eyebrows) Exclusion Criteria: * Previous botulinum toxin therapy * Subjects who are pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control * Subjects planning a facial cosmetic procedure or visible scars * Previous cosmetic surgery to the upper face * Medical condition that may increase their risk of exposure to botulinum toxin including diagnosed Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function * History of facial nerve palsy * Allergy or sensitivity to any component of the study medication

Locations (2)

Unnamed facility

West Palm Beach, Florida, United States

Unnamed facility

Livonia, Michigan, United States

Outcomes

Primary Outcomes

The First Visit Onset of Efficacy as Measured by Physician Assessment

The first visit onset of efficacy as measured by physician assessment. Onset is determined by a yes/no answer to the question "Since injecting the patient, have you noticed any effect on the appearance of the patient's frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14.

Time frame: 14 Days

The First Visit Onset of Efficacy as Measured by Subject Assessment

The first visit onset of efficacy as measured by subject assessment. Onset is determined by a yes/no answer to the question "Since being injected, have you noticed any effect on the appearance of your frown lines (lines between the eyebrows)?" at days 2, 3, 4, 7, and 14.

Time frame: 14 Days

Secondary Outcomes

Average Subject Assessment Score in Improvement of Appearance of Frown Lines

Average subject assessment score in improvement of appearance of frown lines (lines between the eyebrows) as measured by a 7-point scale (1=very much improved and 7=very much worse)on a daily basis. The average scores over the 1st diary week (1-7 days) and the 2nd diary week (8-14 days) are presented.

Time frame: 14 Days

Change From Baseline in Patient Satisfaction as Measured by Facial Line Outcome (FLO) Questionnaire Score

Change from baseline in patient satisfaction as measured by FLO questionnaire comprised of 11 items that assess subject's perceptions about specific aspects of their facial lines for the previous 7 days. Each question is scored on a 11-point scale (0=not at all, 5=somewhat, 10=very much) and the sums are converted to the total FLO score. The minimum total FLO score is 0 (worst) and the maximum total FLO score is 100 (best). The total FLO score was calculated at baseline and Day 14. A positive number change from baseline indicates an improvement.

Time frame: Baseline, Day 14

Percentage of Patients Reporting Self-Perception of Age (SPA)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.